Bill Snyder

COVID treatment studied by VUMC gains FDA approval

Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.

Three from Vanderbilt elected to the National Academy of Medicine

Three members of the Vanderbilt University School of Medicine faculty have been elected this year to the National Academy of Medicine (NAM), the organization announced Monday, Oct. 19.

Clinical trial to test HIV drugs to treat COVID-19

Vanderbilt University Medical Center, in collaboration with the University of Colorado and Beth Israel Deaconess Medical Center in Boston, is leading one of the first “telemedicine” clinical trials to test a potential treatment for COVID-19.

Possible COVID-19 “decoy”

It might be possible to use vesicles carrying the receptor for SARS-CoV-2, the virus that causes COVID-19, to bind the virus and prevent infection.

x-ray of stomach

Factor involved in stomach injury response identified

Researchers at Vanderbilt University Medical Center have identified a key factor that coordinates the body’s repair response to severe injury in the stomach caused, most commonly, by infection by the bacterium Helicobacter pylori.

Posing with the award presented by the Tennessee Hospital Association are (front row, from left) Molly Knostman, PharmD, MHA, C. Wright Pinson, MBA, MD, Patty Wright, MD, Mark Sullivan, PharmD (back row, from left) Halden Van Cleave, PharmD, MS, Deidra Dickerson, PharmD, Garrett Crothers, PharmD, Kevin Scharfman, PharmD, Eric Patton and Ryan Schell, PharmD.

THA honors VUMC efforts in remdesivir distribution

A team of pharmacists and physicians from Vanderbilt University Medical Center that this spring took on statewide distribution of remdesivir, an urgently needed investigational drug for severely ill patients hospitalized with COVID-19, has received the President’s Award from the Tennessee Hospital Association (THA).

1 35 36 37 38 39 115